查看文章

Germ cell tumours (GCT) are the most common malignancies in young men aged between 15 and 35 years. 1 Options for the treatment of patients with primary resistant or relapsed disease include second-line regimens of conventional-dose chemotherapy (CDCT) combining cisplatin and ifosfamide with either vinblastine 2 or paclitaxel 3 or, alternatively, high-dose chemotherapy (HDCT) with autologous stem cell support (autoSCT). 4, 5 In the absence of conclusive evidence from clinical trials, the precise indications for the use of HDCT and autoSCT remain unclear. Since 1993, the Memorial Sloan-Kettering Cancer Center (MSKCC) has been using the TI-CE (two cycles of taxol (paclitaxel)/ifosfamide (TI) followed by three cycles of high-dose carboplatin and etoposide (CE)) regimen in previously treated GCT patients who have the following unfavourable prognostic features:(1) extra-gonadal primary site (primary …